P-190 - Feasibility of using MicroRNAs in early detection of recurrence in colon cancer patients

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Colon and Rectal Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter J. Olsen
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors J. Olsen1, L. Kirkeby2, S. Eiholm2, S. Jørgensen1, O. Pedersen3, P. Jess2, I. Gogenur2, J. Troelsen1
  • 1Roskilde University, Roskilde/DK
  • 2Roskilde Hospital, Roskilde/DK
  • 3Naestved Hospital, Naestved/DK

Abstract

Introduction

Colorectal cancer is one of the most common malignancies in the western world, and the second most common cause of cancer related death. Recurrence after curative intended surgery is associated with high mortality. MicroRNA is a type of noncoding RNA that is approximately 22 nucleotides long. Recent studies have shown that circulating microRNAs can be used as potential diagnostic biomarkers in colon cancer. The use of microRNAs in detecting recurrence is less investigated. Aim: To investigate microRNAs possible application in detecting recurrence in colon cancer patients.

Methods

Patients diagnosed with colon cancer and scheduled for surgery at Roskilde University Hospital were enrolled. Blood samples were drawn before and after surgery and at 3-year follow-up or at the time of diagnosis of recurrence. RNA was extracted from plasma. Based on a pilot study, we selected a panel of 18 microRNAs for further investigation, using RT-qPCR with LNA-primers from Exiqon. The expressions of the different microRNAs were investigated at the three time points with repeated measures ANOVA. Adjustment for multiple t-testing were done using the Benjamini-Hochberg correction.

Results

A total of 25 patients were included (recurrence: n = 11 and non-recurrence: n = 14). Of the 18 microRNAs investigated, 4 significantly changed expression in plasma over time in the recurrence group, when comparing before and after surgery and at the time of recurrence, these were: miR-17.5p (p = 0.004), miR-19a.3p (p = 0.005), miR-106a.5p (p = 0.0073), and miR-106b.5p (p = 0.007). These microRNAs did not significantly change expression in the non-recurrence group.

Conclusion

In this small cohort of colon cancer patients, we show that several microRNAs change expression in plasma with time, in patients with recurrence. It is possible that microRNAs in the future could complement other biomarkers, e.g. CEA, in the routine follow-up of colon cancer patients after surgery.